Literature DB >> 17460461

Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.

Paola Cassoni1, Rebecca Senetta, Isabella Castellano, Erika Ortolan, Martino Bosco, Ivana Magnani, Alessandro Ducati.   

Abstract

Caveolins are basic constituents of flask-shaped cell membrane microdomains (caveolae), which are involved in many cell functions, including signalling, trafficking, and cellular growth control. The distribution of caveolae within the normal brain and in brain tumors is controversial. In the present study, we describe the expression of caveolin-1 (cav-1) in 64 brain tumors of different grade, of either astroglial or oligodendroglial origin. All studied astrocitomas of any grade (from II to IV) were cav-1 positive, displaying staining patterns and intensity specifically associated to the different tumor grades. In all glioblastomas and gliosarcomas, cav-1 staining was extremely intense, typically localized at the cell membrane and recognized a variable percentage of cells, including the majority of spindle cells and palisade-oriented perinecrotic cells. In anaplastic astrocytomas, a less intense membrane staining or a cytoplasmic dotlike immunoreactivity were present, the latter being almost the exclusive pattern observed in diffuse astrocitomas grade II. In contrast to astroglial tumors, the striking totality of grade II oligodendrogliomas and the large majority of grade III were lacking cav-1 expression. Interestingly, a cav-1 distribution overlapping the pattern described in tissues was observed also in primary cell cultures of human glioblastomas and astrocytomas, and also in one established glioblastoma cell line (U251 MG), analyzed by means of confocal microscopy and flow cytometry. In conclusion, among astroglial tumors cav-1 expression varies in distribution, pattern, and intensity specifically according to tumor types and grades. The association between tumor progression and a more structured membranous pattern of cav-1 expression could suggest the hypothesis of a neoplastic shift towards a mesenchymal phenotype, whose behavioral and biologic significance worth further studies. Finally, the lack of cav-1 immunoreactivity in oligodendrogliomas suggests its concrete application as a useful diagnostic marker.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17460461     DOI: 10.1097/01.pas.0000213433.14740.5d

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes.

Authors:  Rebecca Senetta; Clelia Miracco; Salvatore Lanzafame; Luigi Chiusa; Rosario Caltabiano; Antonio Galia; Giulia Stella; Paola Cassoni
Journal:  Neuro Oncol       Date:  2010-11-08       Impact factor: 12.300

Review 2.  Caveolin-1, caveolae, and glioblastoma.

Authors:  Marie-Odile Parat; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2012-04-16       Impact factor: 12.300

3.  Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo.

Authors:  Céline Bruyère; Laurence Abeloos; Delphine Lamoral-Theys; Rebecca Senetta; Véronique Mathieu; Marie Le Mercier; Richard E Kast; Paola Cassoni; Guy Vandenbussche; Robert Kiss; Florence Lefranc
Journal:  Transl Oncol       Date:  2011-04-01       Impact factor: 4.243

4.  Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development.

Authors:  Paulina Kucharzewska; Helena C Christianson; Johanna E Welch; Katrin J Svensson; Erik Fredlund; Markus Ringnér; Matthias Mörgelin; Erika Bourseau-Guilmain; Johan Bengzon; Mattias Belting
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

5.  Nucleolin overexpression is associated with an unfavorable outcome for ependymoma: a multifactorial analysis of 176 patients.

Authors:  Chunjui Chen; Lingchao Chen; Yu Yao; Zhiyong Qin; Hong Chen
Journal:  J Neurooncol       Date:  2015-11-28       Impact factor: 4.130

6.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis.

Authors:  Whitney B Pope; Jenny H Chen; Jun Dong; Marc R J Carlson; Alla Perlina; Timothy F Cloughesy; Linda M Liau; Paul S Mischel; Phioanh Nghiemphu; Albert Lai; Stanley F Nelson
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

7.  Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.

Authors:  Clovis O Da Fonseca; Julio Thome Silva; Igor Rodrigo Lins; Marcela Simão; Adriano Arnobio; Débora Futuro; Thereza Quirico-Santos
Journal:  Invest New Drugs       Date:  2009-01-13       Impact factor: 3.850

8.  Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma.

Authors:  Cristiana Pistol Tanase; Simona Dima; Mihaela Mihai; Elena Raducan; Mihnea Ioan Nicolescu; Lucian Albulescu; Bogdan Voiculescu; Traian Dumitrascu; Linda Maria Cruceru; Mircea Leabu; Irinel Popescu; Mihail Eugen Hinescu
Journal:  J Mol Histol       Date:  2009-01-22       Impact factor: 2.611

Review 9.  Remodelling and Treatment of the Blood-Brain Barrier in Glioma.

Authors:  Yihao Wang; Fangcheng Zhang; Nanxiang Xiong; Hao Xu; Songshan Chai; Haofei Wang; Jiajing Wang; Hongyang Zhao; Xiaobing Jiang; Peng Fu; Wei Xiang
Journal:  Cancer Manag Res       Date:  2021-05-27       Impact factor: 3.989

10.  Caveolin-1 is a negative regulator of tumor growth in glioblastoma and modulates chemosensitivity to temozolomide.

Authors:  Kevin Quann; Donna M Gonzales; Isabelle Mercier; Chenguang Wang; Federica Sotgia; Richard G Pestell; Michael P Lisanti; Jean-François Jasmin
Journal:  Cell Cycle       Date:  2013-04-17       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.